More recently, Chien et al. (2020) found a higher one-year cumulative incidence of CTS in women with breast cancer using aromatase inhibitors (1.4%) versus tamoxifen (0.8%; p=0.008), with a 68% increased CTS risk for aromatase inhibitor users in multivariable analysis [25]. Here, CYP19A1 is linked to breast carcinoma.